No Data
Stoke Therapeutics Finalizes EMPEROR Study Program With Regulatory Agencies
Express News | Stoke Therapeutics : FDA Breakthrough Therapy Designation Positions Zorevunersen on Efficient Development Path; Plans to Start Phase 3 in Mid-2025
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
Stoke Therapeutics(STOK.US) 10% Shareholder Sells US$23 Million in Common Stock
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
